Heart lung transplants

Neuringer IP, Chalermskulrat W, Aris R. Obliterative bronchiolitis or chronic lung allograft rejection a basic science review. J Heart Lung Transplant 2005 24 3-19. [Pg.151]

Vagal neuropathy in diabetes mellitus [145, 146] and truncal vagotomy [147] may markedly change intestinal motility, as do heart-lung transplantation [148]. Spinal cord lesions also alter gut function, but the outlet obstruction due to failure of the striated muscles involved in defecation is more important than the enteric smooth muscle effects [149]. [Pg.14]

Mathias JR, Baskin GS, Reeves-Darby VG, Clench MH, Smith LL, Calhoon JH Chronic intestinal pseudoobstruction in a patient with heart-lung transplant. Dig Dis Sci 1992,37 1761-1768. [Pg.21]

Perrault LP, Malo O, Bidouard JP, Villeneuve N, Vilaine JP, Vanhoutte PM (2003) Inhibiting the NO pathway with intracoronary L-NAME infusion increases endothelial dysfunction and intimal hyperplasia after heart transplantation. J Heart Lung Transplant 22 439-451... [Pg.244]

Cyclosporine has been approved for use in allogeneic kidney, liver, and heart transplant patients and is under study for use in pancreas, bone marrow, single lung, and heart-lung transplant procedures. It is recommended that corticosteroids, such as prednisone, be used concomitantly, although at half or less of their usual dose. Such combined therapy leads to fewer side effects, a decreased incidence of infectious complications, efficacy of lower doses of cyclosporine, and a better history of patient survival. [Pg.659]

Ahmed SM, Banner NR, Dubrey S W Low cyclosporin-A level due to Saint-John s-wort in heart transplant patients (letter). J Heart Lung Transplant 20 795, 2001... [Pg.9]

Reichenspurner H Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 2005 24 119. [PMID 15701425]... [Pg.1209]

The first combined heart-lung transplant was performed in 1981 at Stanford University. Combined heart-lung donors need to satisfy both the requirements already described separately. Combined heart-lung transplant is recommended in patients with congenital problems affecting these organs, pulmonary hypertension and/or cystic fibrosis. The recipients for the combined transplant are recommended to be less than 55 years old. Survival rates are 79, 66, and 54% at 1 month, 1 year and 3 years, respectively, after transplantation. [Pg.165]

Betkowski AS, Graff R, Chen JJ, HauptmanPJ. 2002. Panel- reactive antibody screening practices prior to heart transplantation. J Heart Lung Transplant. 21 644-650. [Pg.167]

Mancini MC. 2006. Heart-lung transplantation, www.emedicine.com/med/topic2063.htm. [Pg.169]

Pinderski LJ, Kirklin JK, McGiffin D, Brown R, et al. 2005. Multi-organ transplantation Is there a protective effect against acute and chronic rejection J Heart Lung Transplant. 24 1828-1833. [Pg.169]

Higenbottam TW, Spiegelhalter D, Scott JP, Fuster V, Dinh-Xuan AT, Caine N, Wallwork J. Prostacyclin (epo-prostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993 70(4) 366-70. [Pg.109]

Schofield RS, Hill JA, McGinn CJ, Aranda JM. Hormone therapy in men and risk of cardiac allograft rejection. J Heart Lung Transplant 2002 21(4) 493-5. [Pg.494]

Iwata, A., Sai, S., Moore, M., Nyhuis, J., de Fries-Hallstrand, R., Quetingco, G.C. et al. (2000) Gene therapy of transplant arteriopathy by hposome-mediated transfection of endothelial nitric oxide synthase. J. Heart Lung Transplant, 19, 1017-1028. [Pg.466]

TABLE 6.2. The Effect of Size of the FSC/SSC Gate on Determination of the Characteristics of Cells Within that Gate Peripheral Blood Mononuclear Cells from a Heart/Lung Transplant Patient ... [Pg.103]

Brodde, O.-E., Hillemann, S., Kunde, K., Vogesang, M., and Zerkowski, H.-R. 1992. Receptor systems affecting force of contraction in the human heart and their alterations in chronic heart failure. J. Heart Lung Transplant. 11 S164-S174. [Pg.172]

Musameh MD, Green CJ, Mann BE, Fuller BJ, Motterlini R (2007) J Heart Lung Transplant 26 1192... [Pg.282]

Beranek JT. Further evidence of cardiomyocyte apoptosis in humoral (microvascular) rejection of human cardiac allografts. J Heart Lung Transplant 2004 23 378-379. [Pg.39]

Waid TH, Thompson JS, McKeown JW, Brown SA, Sekela ME. Induction immunotherapy in heart transplantation with T10B9.1A-31 a phase I study. J Heart Lung Transplant 1997 16 913-16. [Pg.239]

Wright DH, Lake KD, Bruhn PS, Emery RW Jr. Nefazodone and cyclosporine drug-drug interaction. J Heart Lung Transplant 1999 18(9) 913-5. [Pg.108]

Bhorade SM, Vigneswaran W, McCabe MA, Garrity ER. Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. J Heart Lung Transplant 2000 19 1199-204. [Pg.527]

A77 1726, the active metabolite of Leflunomide does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. J. Heart Lung Transplant. 14,1016-1030. [Pg.203]

Dunn, M. ). (1995). Assodation of pretransplantation antiheart antibodies with clinical course after heart transplantation. J. Heart Lung Transplant. 14, 119-126. [Pg.314]

Esmore D, Keogh A, Spratt P, Jones B, Chang V. Heart transplantation in females. J Heart Lung Transplant 1991 10 335-41. [Pg.338]

Kilpatrick NM, Weintraub RG, Lucas JO, Shipp A, Byrt T, Wilkinson JL. Gingival overgrowth in pediatric heart and heart-lung transplant recipients. J Heart Lung Transplant 1997 16(12) 1231-7. [Pg.764]

Caforio AL, Gambino A, Tona F, Feltrin G, Marchini F, Pompei E, Testolin L, Angelini A, Dalla Volta S, Casarotto D. Sulfinpyrazone reduces cyclosporine levels a new drug interaction in heart transplant recipients. J Heart Lung Transplant 2000 19(12) 1205-8. [Pg.770]

Park MH, Pelegrin D, Haug MT 3rd, Young JB. Troghtazone, a new antidiabetic agent, decreases cyclosporine level. J Heart Lung Transplant 1998 17(11) 1139 10. [Pg.770]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...